Lundbeck Australia

20 PBAC submissions on file, active 2007–2025. 70% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Aripiprazole
  Mental health · Recommended · 2025—
• Asenapine
  Psychiatry · Recommended with restriction · 2011—
• Brexpiprazole
  Mental health · Recommended · 2025—
• Escitalopram
  Mental health · Recommended · 2014—
• Escitalopram oxalate
  Mental health · Recommended with restriction · 2008—
• Memantine hydrochloride
  Neurology · Recommended with restriction · 2008—
• Rasagiline
  Neurology · Recommended with restriction · 2012—
• Eptinezumab
  Neurology · Recommended with restriction · 2022—
• Nalmefene
  Mental health · Not recommended · 2015—
• Sertindole
  Mental health · Not recommended · 2011—
• Vortioxetine
  Mental health · Not recommended · 2014—

Therapy area mix

Activity by year

2007 (2) · 2008 (3) · 2011 (4) · 2012 (1) · 2014 (3) · 2015 (1) · 2017 (1) · 2018 (1) · 2022 (1) · 2024 (1) · 2025 (2)

Rejection patterns

Across 6 Not recommended decisions on file.

• 1×uncertain clinical relevance of efficacy
• 1×inappropriate comparator weighting (one-third assumption not justified)
• 1×concerns about trial population not reflective of PBS population (excluded mental health comorbidities)
• 1×questions about non-inferiority to naltrexone
• 1×uncertain cost-minimisation assumptions